Ian Birch

Managing Director
20+ years of professional experience
Specializes in technology corporate finance
Expert in technology consulting and transformation and cloud managed services
London
@alvarezmarsal
LinkedIn
Copied!
Ian Birch is a Managing Director with Alvarez & Marsal Corporate Finance in Birmingham. He specializes in technology corporate finance, focusing on technology services including technology consulting and transformation and cloud managed services. Mr. Birch also has experience across vertical software, digital platforms and technology reselling/distribution.

With more than 20 years of professional experience, Mr. Birch has operated extensively in the regional market, supporting entrepreneurs, private equity firms and corporates through exits, equity raises and acquisitions.

Mr. Birch’s notable assignments include the acquisition of Kick ICT, BCN and Mobysoft, the sale of Tisski, 101Ways, REPL and Node4. He has worked with clients across various industries, including travel and travel technology and construction technology and healthcare technology, digital marketplaces and craft beer.

Prior to joining A&M, Mr. Birch spent 20 years with PwC, serving most recently as Head of IT Services Corporate Finance, where he played a key role in re-establishing the technology corporate finance team.

Mr. Birch earned a bachelor’s degree in economics from Lancaster University. He is a chartered account with the Institute of Chartered Accounts Scotland.

Insights By This Professional

The explosive growth in cyberattacks and major technical shifts introduced by AI and cloud technologies are just a few of the drivers fueling sustained demand for cybersecurity services in recent years.
London, 4 November 2024 – Leading global professional services firm Alvarez & Marsal (A&M) continues to strengthen its Corporate Finance practice in the UK with the appointment of Ian Birch as a Managing Director in Birmingham. At A&M, he will build out the practice’s technology M&A capability across Europe.
Latest insights The latest insights from Ian Birch 's team
Thought Leadership
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).